Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1962 1
1979 4
1980 1
1982 4
1983 3
1984 8
1985 3
1986 5
1987 8
1988 9
1989 11
1990 12
1991 11
1992 14
1993 16
1994 18
1995 22
1996 28
1997 39
1998 53
1999 37
2000 74
2001 65
2002 92
2003 113
2004 131
2005 146
2006 168
2007 208
2008 268
2009 334
2010 424
2011 556
2012 655
2013 753
2014 878
2015 997
2016 1034
2017 1150
2018 1362
2019 1646
2020 1963
2021 2244
2022 2591
2023 2617
2024 977

Text availability

Article attribute

Article type

Publication date

Search Results

19,348 results

Results by year

Filters applied: . Clear all
Page 1
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M. Carbone DP, et al. Among authors: yuan y. J Immunother Cancer. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189. J Immunother Cancer. 2024. PMID: 38346853 Free PMC article. Clinical Trial.
Targeting inflammation as cancer therapy.
Wang M, Chen S, He X, Yuan Y, Wei X. Wang M, et al. Among authors: yuan y. J Hematol Oncol. 2024 Mar 22;17(1):13. doi: 10.1186/s13045-024-01528-7. J Hematol Oncol. 2024. PMID: 38520006 Free PMC article. Review.
Ferroptosis and its current progress in gastric cancer.
Yue Z, Yuan Y, Zhou Q, Sheng J, Xin L. Yue Z, et al. Among authors: yuan y. Front Cell Dev Biol. 2024 Feb 28;12:1289335. doi: 10.3389/fcell.2024.1289335. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38481532 Free PMC article. Review.
Automated high-throughput DNA synthesis and assembly.
Ma Y, Zhang Z, Jia B, Yuan Y. Ma Y, et al. Among authors: yuan y. Heliyon. 2024 Feb 25;10(6):e26967. doi: 10.1016/j.heliyon.2024.e26967. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38500977 Free PMC article. Review.
The Contributions of Thrombospondin-1 to Epilepsy Formation.
Cheng Y, Zhai Y, Yuan Y, Wang Q, Li S, Sun H. Cheng Y, et al. Among authors: yuan y. Neurosci Bull. 2024 Mar 26. doi: 10.1007/s12264-024-01194-2. Online ahead of print. Neurosci Bull. 2024. PMID: 38528256 Review.
Targeting Wnt signaling for improved glioma immunotherapy.
Gutova M, Hibbard JC, Ma E, Natri HM, Adhikarla V, Chimge NO, Qiu R, Nguyen C, Melendez E, Aguilar B, Starr R, Yin H, Rockne RC, Ono M, Banovich NE, Yuan YC, Brown CE, Kahn M. Gutova M, et al. Among authors: yuan yc. Front Immunol. 2024 Feb 21;15:1342625. doi: 10.3389/fimmu.2024.1342625. eCollection 2024. Front Immunol. 2024. PMID: 38449858 Free PMC article.
Targeting pro-inflammatory T cells as a novel therapeutic approach to potentially resolve atherosclerosis in humans.
Fan L, Liu J, Hu W, Chen Z, Lan J, Zhang T, Zhang Y, Wu X, Zhong Z, Zhang D, Zhang J, Qin R, Chen H, Zong Y, Zhang J, Chen B, Jiang J, Cheng J, Zhou J, Gao Z, Liu Z, Chai Y, Fan J, Wu P, Chen Y, Zhu Y, Wang K, Yuan Y, Huang P, Zhang Y, Feng H, Song K, Zeng X, Zhu W, Hu X, Yin W, Chen W, Wang J. Fan L, et al. Among authors: yuan y. Cell Res. 2024 Mar 15. doi: 10.1038/s41422-024-00945-0. Online ahead of print. Cell Res. 2024. PMID: 38491170
19,348 results
You have reached the last available page of results. Please see the User Guide for more information.